ResearcherThe Ohio State University Wexner Medical CenterActive in the last 2 years
Samantha M. Ruff
Matched on ORCID iD 0000-0001-5275-6705; OpenAlex author ID A5054890127. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2022: 1 paper · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper · 2026: 1 paper
Papers 7
- Neoadjuvant therapy in frail patients with pancreatic cancer: Impact on surgical safety and outcomes. Co-author DOI 10.1016/j.surg.2026.110256↗
- Comprehensive Analysis of Genomic Variations in Pancreatic Adenocarcinoma by Race. Co-author DOI 10.1002/cam4.71346↗
- Evaluating the caregiver experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27558↗
- Use of Diagnostic Laparoscopy and Peritoneal Washings for Pancreatic Cancer. Co-author DOI 10.1016/j.suc.2024.05.004↗
- Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review. Co-author DOI 10.31083/j.fbl2903101↗
- Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving versus Non-Minority-Serving Hospitals. Co-author DOI 10.1245/s10434-023-13230-y↗
- Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evidence. First author DOI 10.1016/j.coph.2022.102305↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Timothy Michael Pawlik · 3 shared papers, 2023–2024 · strength 0.82
- Paper Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review. DOI 10.31083/j.fbl2903101↗
- Paper Evaluating the caregiver experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma. DOI 10.1002/jso.27558↗
- Paper Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Servin… DOI 10.1245/s10434-023-13230-y↗
- Jordan M. Cloyd · 3 shared papers, 2022–2024 · strength 0.62
- Paper Routine neoadjuvant chemotherapy for all patients with resectable pancreatic ductal adenocarcinoma? A review of the evi… DOI 10.1016/j.coph.2022.102305↗
- Paper Evaluating the caregiver experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma. DOI 10.1002/jso.27558↗
- Paper Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Servin… DOI 10.1245/s10434-023-13230-y↗
- Elio R. Bitar · 2 shared papers, 2025–2026 · strength 0.56
- Mohamad N. El Moheb · 2 shared papers, 2025–2026 · strength 0.56
- Allan Tsung · 2 shared papers, 2025–2026 · strength 0.56
- Susan Tsai · 1 shared paper, 2024 · strength 0.46
- Mary E. Dillhoff · 2 shared papers, 2023–2024 · strength 0.36
- Aslam M. Ejaz · 2 shared papers, 2023–2024 · strength 0.36
- Olivia Sears · 1 shared paper, 2026 · strength 0.32
- Zachary J. Brown · 1 shared paper, 2022 · strength 0.26
- Lena Stevens · 1 shared paper, 2024 · strength 0.21
- Chanza Fahim Shaikh · 1 shared paper, 2023 · strength 0.15
- Yutaka Endo · 1 shared paper, 2023 · strength 0.15
- Muhammad Musaab Munir · 1 shared paper, 2023 · strength 0.15
- Erryk Katayama · 1 shared paper, 2023 · strength 0.15
- Henrique Araujo Lima · 1 shared paper, 2023 · strength 0.15
- Joal D. Beane · 1 shared paper, 2023 · strength 0.15
- Zorays Moazzam · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.